Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Shares Outstanding (Diluted Average): 2019-2025

Historic Shares Outstanding (Diluted Average) for Summit Therapeutics (SMMT) over the last 3 years, with Sep 2025 value amounting to $743.4 million.

  • Summit Therapeutics' Shares Outstanding (Diluted Average) rose 2.31% to $743.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $743.4 million, marking a year-over-year increase of 2.31%. This contributed to the annual value of $718.5 million for FY2024, which is 15.96% up from last year.
  • Summit Therapeutics' Shares Outstanding (Diluted Average) amounted to $743.4 million in Q3 2025, which was up 0.11% from $742.6 million recorded in Q2 2025.
  • In the past 5 years, Summit Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $743.4 million in Q3 2025 and a low of $131.7 million during Q4 2021.
  • In the last 3 years, Summit Therapeutics' Shares Outstanding (Diluted Average) had a median value of $707.9 million in 2024 and averaged $679.3 million.
  • Data for Summit Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 233.99% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Summit Therapeutics' Shares Outstanding (Diluted Average) stood at $131.7 million in 2021, then spiked by 46.78% to $193.3 million in 2022, then skyrocketed by 220.50% to $619.6 million in 2023, then increased by 15.96% to $718.5 million in 2024, then increased by 2.31% to $743.4 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $743.4 million for Q3 2025, versus $742.6 million for Q2 2025 and $738.1 million for Q1 2025.